Sanofi

Paul Hudson faces down French unions in fight to restructure Sanofi
Paul Hudson faces down French unions in fight to restructure Sanofi
Endpoints
Sanofi
Pharma CEOs
Paul Hudson
France
unions
Flag link:
AstraZeneca, Sanofi, Eli Lilly sue HHS over 340B opinion
AstraZeneca, Sanofi, Eli Lilly sue HHS over 340B opinion
Beckers Hospital Review
Eli Lilly
Sanofi
AstraZeneca
HHS
340B
discounts
Flag link:
The top 10 largest biopharma M&A deals in 2020
The top 10 largest biopharma M&A deals in 2020
Fierce Pharma
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Gilead Sciences
Forty Seven
Merck
VelosBio
Nestle
Aimmune
Immunomedics
JNJ
Momenta Pharmaceuticals
Sanofi
Principia Biopharma
Bayer
Asklepios BioPharmaeutical
Flag link:
JPM: Sanofi's new chief digital officer steps up ambitions in marketing, research and even e-commerce
JPM: Sanofi's new chief digital officer steps up ambitions in marketing, research and even e-commerce
Fierce Pharma
JPMHC 2021
Sanofi
digital pharma
Flag link:
Sanofi has a name for its ingredients spinoff, taps Centrient head Karl Rotthier as first CEO
Sanofi has a name for its ingredients spinoff, taps Centrient head Karl Rotthier as first CEO
Endpoints
Sanofi
Paul Hudson
spinoffs
APIs
EuroAPI
Flag link:
Sanofi inks $1.1B Kymab buyout to bag midphase eczema drug
Sanofi inks $1.1B Kymab buyout to bag midphase eczema drug
Fierce Biotech
Sanofi
Kymab
M&A
atopic dermatitis
eczema
monoclonal antibodies
Flag link:
Sanofi Executives Predict 2021 Will be 'Transformative' Year for Company
Sanofi Executives Predict 2021 Will be 'Transformative' Year for Company
BioSpace
Sanofi
Flag link:
Biopharma Companies Entering 2021 With New Collabs, Partnerships
Biopharma Companies Entering 2021 With New Collabs, Partnerships
BioSpace
M&A
Argenx
Zai Lab
Dewpoint Therapeutics
Pfizer
CureVac
Bayer
Sanofi
Nurix Therapeutics
Flag link:
Roche, Sanofi arthritis drugs reduce death rates among sickest COVID-19 patients
Roche, Sanofi arthritis drugs reduce death rates among sickest COVID-19 patients
Reuters
COVID-19
Roche
Actemra
Sanofi
Kevzara
Flag link:
Pfizer, AbbVie, BMS, Teva, Sanofi, Gilead and others ring in 2021 with nearly 600 price hikes
Pfizer, AbbVie, BMS, Teva, Sanofi, Gilead and others ring in 2021 with nearly 600 price hikes
Fierce Pharma
drug pricing
Pfizer
AbbVie
Teva Pharmaceutical
Sanofi
Gilead Sciences
Flag link:
The top 5 pharma M&A deals of 2020
The top 5 pharma M&A deals of 2020
Pharmaforum
M&A
AstraZeneca
Alexion
Gilead Sciences
Immunomedics
Forty Seven
JNJ
Momenta
Sanofi
Principia Biopharma
Flag link:
13 drugmakers contracted by Operation Warp Speed in 2020
13 drugmakers contracted by Operation Warp Speed in 2020
Beckers Hospital Review
HHS
Operation Warp Speed
COVID-19
vaccines
Cytiva
Eli Lilly
AstraZeneca
Emergent BioSolutions
Fujifilm
JNJ
Moderna Therapeutics
Pfizer
BioNTech
Novavax
Regeneron
Sanofi
GSK
Flag link:
Sanofi promised pandemic hazard pay to vaccine plant workers, then offered 3 days off instead, lawsuit says
Sanofi promised pandemic hazard pay to vaccine plant workers, then offered 3 days off instead, lawsuit says
Fierce Pharma
Sanofi
drug manufacturing
COVID-19
vaccines
pandemic
Flag link:
Weak clinical data force Sanofi, GSK to delay COVID-19 vaccine
Weak clinical data force Sanofi, GSK to delay COVID-19 vaccine
Fierce Biotech
Sanofi
GSK
vaccines
COVID-19
clinical trials
Flag link:
Sanofi accepts a lengthy delay as its hemophilia drug fitusiran resumes a PhIII after safety fears forced a halt
Sanofi accepts a lengthy delay as its hemophilia drug fitusiran resumes a PhIII after safety fears forced a halt
Endpoints
Sanofi
fitusiran
FDA
hemophilia
Flag link:
Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia
Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia
Pharmaceutical Business Review
rilzabrutinib
fast track
FDA
Sanofi
Principia Biopharma
chronic immune thrombocytopenia
Flag link:
FDA to expedite development of two Sanofi rare disease drugs
FDA to expedite development of two Sanofi rare disease drugs
Pharmaforum
Sanofi
FDA
Rare Diseases
Pompe disease
Avalglucosidase alfa
Flag link:
Sanofi grapples with rejection of potential first-in-class orphan drug, faults third-party manufacturing
Sanofi grapples with rejection of potential first-in-class orphan drug, faults third-party manufacturing
Endpoints
Sanofi
sutimlimab
orphan drugs
FDA
drug manufacturing
Flag link:
France’s Medicine Watchdog Indicted Over Sanofi’s Birth Defect-Causing Drug
France’s Medicine Watchdog Indicted Over Sanofi’s Birth Defect-Causing Drug
BioSpace
Sanofi
Depakine
France
epilepsy
Flag link:
Doubling down on Sanofi's French roots, Paul Hudson infuses €50M into Jeito Capital to boost homegrown biotechs
Doubling down on Sanofi's French roots, Paul Hudson infuses €50M into Jeito Capital to boost homegrown biotechs
Endpoints
Paul Hudson
Sanofi
Jeito Capital
Flag link:

Pages